Effects of Metoclopramide and Hyoscine-N-Butyl Bromide on Motility of Duodenum in Male Rats and Quantum Computational Analysis

Öz

Abstract: Gastroenteritis with emesis is routinely treated with metoclopramide. An anticholinergic substance called hyoscine-N-butyl bromide (buscopan) prevents acetylcholine from acting on muscarinic receptors. This study aimed to ascertain how metoclopramide affected the duodenum motility caused by acetylcholine. Another objective is to examine the impact of metoclopramide alone and in combination with hyoscine-n-butyl bromide on duodenal motility. In this examination, the duodenum was separated by 1 cm, and 2 cm long strips of tissue were produced and fastened with both sides of surgical silk at both ends of the isolated organ bath. Tissue was then suspended from the device and isometric contractions were recorded. Acetylcholine was introduced to the duodenum (10-4 M). Metoclopramide (35 M), hyoscine-N-butyl bromide (15 M), and metoclopramide and hyoscine-N-butyl bromide (50 M) were added and incubated after 10 minutes. The duodenum displayed frequency, peak-to-peak, and amplitude responses to metoclopramide (35 M), hyoscine-N-butyl bromide (15 M), and metoclopramide and hyoscine-N-butyl (50 M) in this result. Based on quantum chemical calculations several chemical properties were studied and to determine the active center the Fukui function was considered.

Anahtar Kelimeler

• Duodenum
• Metoclopramide
• Hyoscine-N-Butylbromide
• DFT.

Kaynakça

1. [1] J. Chamley-Campbell, G. R. Campbell, and R. Ross, ‘‘The smooth muscle cell in culture,’’ Physiological reviews, vol. 59, no. 1, pp. 1–61, 1979.
2. [2] R. A. Meiss, ‘‘Skeletal muscle and smooth muscle,’’ Structure, pp. 152–176, 2003.
3. [3] S. McGurk, ‘‘Ganong’s review of medical physiology–,’’ Nursing Standard, vol. 24, no. 20, pp. 30–31, 2010.
4. [4] E. Kacar, Z. Ercan, I. Serhatlioglu, A. Sumer, H. Kelestimur, and S. Kutlu, ‘‘The effects of apelin on myometrium contractions in pregnant rats,’’ Cellular and Molecular Biology, vol. 64, no. 11, pp. 74–79, 2018.
5. [5] D. M. Williams and B. K. Rubin, ‘‘Clinical pharmacology of bronchodilator medications,’’ Respiratory Care, vol. 63, no. 6, pp. 641–654, 2018.
6. [6] I. Henzi, B. Walder, and M. Tramer, ‘‘Metoclopramide in the prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized, placebo-controlled studies.’’ British Journal of Anaesthesia, vol. 83, no. 5, pp. 761–771, 1999.
7. [7] C. Maltepe and G. Koren, ‘‘The management of nausea and vomiting of pregnancy and hyperemesis gravidarum–a 2013 update.’’ Journal of Population Therapeutics and Clinical Pharmacology= Journal de la Therapeutique des Populations et de la Pharmacologie Clinique, vol. 20, no. 2, pp. e184–92, 2013.
8. [8] M. Tonini, S. M. Candura, E. Messori, and C. A. Rizzi, ‘‘Therapeutic potential of drugs with mixed 5-ht4 agonist/5-ht3 antagonist action in the control of emesis,’’ Pharmacological research, vol. 31, no. 5, pp. 257–260, 1995.

9. [9] H. S. Smith and A. Laufer, ‘‘Opioid induced nausea and vomiting,’’ European journal of pharmacology, vol. 722, pp. 67–78, 2014.
10. [10] A. R. Van Gool, J. K. Doorduijn, and C. Seynaeve, ‘‘Severe akathisia as a side effect of metoclopramide,’’ Pharmacy world & science, vol. 32, pp. 704–706, 2010.
11. [11] A. O. Ibiloglu, ‘‘Metoclopramide induced akathisia: a case report,’’ Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology, vol. 23, no. 2, pp. 186–189, 2013.
12. [12] R. S. Sandler, W. F. Stewart, J. N. Liberman, J. A. Ricci, and N. L. Zorich, ‘‘Abdominal pain, bloating, and diarrheain the united states,’’ Digestive diseases and sciences, vol. 45, pp. 1166–1171, 2000.
13. [13] L. Chang, O. Y. Lee, B. Naliboff, M. Schmulson, and E. A. Mayer, ‘‘Sensation of bloating and visible abdominal distension in patients with irritable bowel syndrome,’’ Official journal of the American College of Gastroenterology| ACG, vol. 96, no. 12, pp. 3341–3347, 2001.
14. [14] S. Evangelista, ‘‘Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome,’’ Current pharmaceutical design, vol. 10, no. 28, pp. 3561–3568, 2004.
15. [15] S. Y. Omar, D. M. Mamand, R. A. Omer, R. F. Rashid, and M. I. Salih, ‘‘Investigating the role of metoclopramide and hyoscine-n-butyl bromide in colon motility,’’ Aro-The Scientific Journal of Koya University, vol. 11, no. 2, pp. 109–115, 2023.
16. [16] S. Mt-Isa, S. Tomlin, A. Sutcliffe, M. Underwood, P. Williamson, N. M. Croft, and D. Ashby, ‘‘Prokinetics prescribing in paediatrics: evidence on cisapride, domperidone, and metoclopramide,’’ Journal of pediatric gastroenterology and nutrition, vol. 60, no. 4, pp. 508–514, 2015.
17. [17] L. Zhang, J. Song, T. Bai, X. Lu, G. Yang, W. Qian, R. Wang, and X. Hou, ‘‘Effects of buscopan on human gastrointestinal smooth muscle activity in an ex vivo model: Are there any differences for various sections?’’ European Journal of Pharmacology, vol. 780, pp. 180–187, 2016.
18. [18] J. Stadaas and S. Aune, ‘‘The effect of metoclopramide (primperan®) on gastric motility before and after vagotomy in man,’’ Scandinavian Journal of Gastroenterology, vol. 6, no. 1, pp. 17–21, 1971.
19. [19] L. A. Samuels, ‘‘Pharmacotherapy update: Hyoscine butylbromide in the treatment of abdominal spasms,’’ Clinical Medicine. Therapeutics, vol. 1, pp. CMT– S1134, 2009.
20. [20] H. M. Qadr and D. M. Mamand, ‘‘Molecular structure and density functional theory investigation corrosion inhibitors of some oxadiazoles,’’ Journal of Bio-and Tribo-Corrosion, vol. 7, no. 4, p. 140, 2021.
21. [21] S. Stoll and A. Schweiger, ‘‘Easyspin, a comprehensive software package for spectral simulation and analysis in epr,’’ Journal of magnetic resonance, vol. 178, no. 1, pp. 42–55, 2006.